FHL2 and breast carcinoma: The G2/M transition was found to be accelerated when FHL2 expression is suppressed in breast cancer MDA‐MB 231 cells, and the induction of the FHL2 target gene, the cell cycle inhibitor p21, was responsible for this event when cells were treated with the DNA damaging agent doxorubicin [20].